Closely monitor complete blood & platelet counts at regular intervals, more frequently in patients who develop cytopaenias; renal & hepatic function prior to, during active treatment & following therapy; resp status, BP, fluid balance & wt throughout & immediately after the 5-day administration period. Discontinue immediately if substantial increases in creatinine, liver enzymes &/or bilirubin are observed. Severe bone marrow suppression. Haemorrhage. Monitor for signs & symptoms of infection, enterocolitis, or tumour lysis syndrome & cytokine release. Discontinue if exfoliative or bullous rash or if Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected. Discontinue immediately if systemic inflammatory response syndrome, capillary leak syndrome, substantial organ dysfunction, or hypotension occurs. Patients w/ cardiac disease & those taking medicinal products known to affect BP or cardiac function. Mild to moderate renal & hepatic insufficiency. Avoid dehydration. Reduce dose if grade 4 neutropenia occurs. Hepatotoxic adverse reactions. Higher risk of hepatotoxicity suggestive of veno-occlusive disease in patients who previously received a hematopoietic stem cell transplant. Patients on a controlled Na diet. May impair ability to drive or operate machinery. Females of childbearing potential & sexually active males must use effective methods of contraception during treatment. Pregnancy. Childn <1 yr, adult including elderly.
Sign Out
